These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

866 related items for PubMed ID: 28704381

  • 1. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
    Dalgard O, Weiland O, Noraberg G, Karlsen L, Heggelund L, Färkkilâ M, Balslev U, Belard E, Øvrehus A, Skalshøi Kjær M, Krarup H, Thorup Røge B, Hallager S, Madsen LG, Lund Laursen A, Lagging M, Weis N.
    PLoS One; 2017; 12(7):e0179764. PubMed ID: 28704381
    [Abstract] [Full Text] [Related]

  • 2. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
    Pellicelli A, Messina V, Giannelli V, Distefano M, Palitti VP, Vignally P, Tarquini P, Izzi A, Moretti A, Babudieri S, Dell'Isola S, Marignani M, Scifo G, Iovinella V, Cariti G, Pompili M, Candilo FD, Fontanella L, Ettorre GM, Vennarecci G, Ippolito AM, Barbarini G.
    Gut Liver; 2020 May 15; 14(3):357-367. PubMed ID: 30970444
    [Abstract] [Full Text] [Related]

  • 3. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS, Shahoumian TA, Loomis TP, Mole LA, Backus LI.
    J Hepatol; 2019 Jan 15; 70(1):15-23. PubMed ID: 30266283
    [Abstract] [Full Text] [Related]

  • 4. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
    Shiha G, Soliman R, ElBasiony M, Hassan AA, Mikhail NNH.
    Hepatol Int; 2018 Jul 15; 12(4):339-347. PubMed ID: 29663115
    [Abstract] [Full Text] [Related]

  • 5. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    Sirinawasatien A, Techasirioangkun T.
    PLoS One; 2020 Jul 15; 15(2):e0229517. PubMed ID: 32106270
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
    Tao T, Jiang X, Chen Y, Song Y.
    Int J Infect Dis; 2017 Feb 15; 55():56-71. PubMed ID: 28040553
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
    Moshyk A, Martel MJ, Tahami Monfared AA, Goeree R.
    J Med Econ; 2016 Feb 15; 19(2):181-92. PubMed ID: 26453248
    [Abstract] [Full Text] [Related]

  • 8. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
    Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, Berg T, Spengler U, Weiland O, van der Valk M, Rockstroh J, Peck-Radosavljevic M, Zhao Y, Jimenez-Exposito MJ, Zeuzem S.
    Gut; 2016 Nov 15; 65(11):1861-1870. PubMed ID: 27605539
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
    Satsangi S, Mehta M, Duseja A, Taneja S, Dhiman RK, Chawla Y.
    J Gastroenterol Hepatol; 2017 Apr 15; 32(4):859-863. PubMed ID: 27624314
    [Abstract] [Full Text] [Related]

  • 11. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
    Steinebrunner N, Sprinzl MF, Zimmermann T, Wörns MA, Zimmerer T, Galle PR, Stremmel W, Eisenbach C, Stein K, Antoni C, Schattenberg JM, Pathil A.
    BMC Gastroenterol; 2015 Aug 04; 15():97. PubMed ID: 26239732
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
    Alonso S, Riveiro-Barciela M, Fernandez I, Rincón D, Real Y, Llerena S, Gea F, Olveira A, Fernandez-Carrillo C, Polo B, Carrión JA, Gómez A, Devesa MJ, Baliellas C, Castro Á, Ampuero J, Granados R, Pascasio JM, Rubín A, Salmeron J, Badia E, Planas JM, Lens S, Turnes J, Montero JL, Buti M, Esteban R, Fernández-Rodríguez CM.
    J Viral Hepat; 2017 Apr 04; 24(4):304-311. PubMed ID: 27935168
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection.
    Liu CH, Su TH, Liu CJ, Hong CM, Yang HC, Tseng TC, Chen PJ, Chen DS, Kao JH.
    J Gastroenterol Hepatol; 2019 Sep 04; 34(9):1620-1625. PubMed ID: 30693965
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients.
    Shin HP, Burman B, Kozarek RA, Zeigler A, Wang C, Lee H, Zehr T, Edwards AM, Siddique A.
    Gut Liver; 2017 Sep 15; 11(5):711-720. PubMed ID: 28651301
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.